
Clinical Trials Arena2d agobullish
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar winJ&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

J&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.